Journal article icon

Journal article

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Abstract:

Background: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study.

Methods: PASDAS (cut-off scores: remission ≤ 1.9; LDA > 1.9 and < 3.2; Moderate D...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1186/s13075-018-1773-y

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
ORCID:
0000-0002-4756-663X
Expand authors...
Novartis Pharma More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
Arthritis Research and Therapy Journal website
Volume:
20
Article number:
272
Publication date:
2018-12-07
Acceptance date:
2018-11-21
DOI:
EISSN:
1478-6362
ISSN:
1465-9905
Source identifiers:
945724
Keywords:
Pubs id:
pubs:945724
UUID:
uuid:d4f2b614-25c7-4e5f-ba9f-887cd045df3c
Local pid:
pubs:945724
Deposit date:
2018-11-22

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP